First-in-human Study of SAR443765 in Healthy Participants and in Asthmatic Participants
Status:
Not yet recruiting
Trial end date:
2022-12-16
Target enrollment:
Participant gender:
Summary
This is a 3-part, parallel group treatment, Phase 1, randomized, double-blind,
placebo-controlled study to assess the safety, tolerability and pharmacokinetics after
sequential single and multiple ascending doses of SAR443765 in healthy adult participants,
and after a single dose of SAR443765 in participants with mild-to-moderate asthma.